Full clinical cases submission template TITLE OF CASE Do not include "a case report" From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions SUMMARY Up to 150 words summarising the case presentation and outcome (this will be freely available online)
We present the case of a 68 year old male admitted to hospital with severe acute kidney injury secondary to statin-induced rhabdomyolysis. Five weeks previously the patient commenced a course of clarithromycin for infection of a finger wound with Mycobacterium marinum. His current medications included Simvastatin whichSimvastatin that he continued along with clarithromycin.
The severity of the acute kidney injury necessitated initial continuous venovenous haemofiltration followed by twelve haemodialysis sessions before a spontaneous improvement in renal function occurred.
Statins are widely prescribed and we report this case to encourage increased vigilance in avoiding drug interactions known to increase the risk of statin-induced myopathy, including macrolide antibiotics, calcium channel antagonists and amiodarone. The authors would also like to highlight recent guidance on atorvastatin as the statin of choice in patients with chronic kidney disease, and of the need for dose adjustment in those with estimated glomerular filtration rate less than 30mls/min/1.73m².
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BACKGROUND Why you think this case is important -why did you write it up?
In 2013 Prescription Cost Analysis revealed simvastatin to be the most commonly prescribed drug in England, with 39.9 million prescriptions dispensed that year 2 . Whilst the benefits of this drug in reducing cardiovascular risk are evident, and the side effects relatively rare, the large number of patients taking statins demands particular vigilance towards intolerance and drug interactions 3 . Myopathy and muscle disorders are the commonest side effect of statins, with rhabdomyolysis being the most serious 3 . We report this case to illustrate the morbidity associated with a case of statin-induced rhabdomyolysis, and to emphasise the on-going requirement for regular review of statin dosage and medication interactions.
CASE PRESENTATION Presenting features, medical/social/family history
A 68 year old man presented to hospital with a seven day history of increasing thigh pain and progressive proximal myopathy. Prior to this he was fit and independent. Past medical history included hypertension, hypercholesterolemia, chronic kidney disease stage 3a, gastro-oesophageal reflux disease and thrombocytopenia of unknown cause, which had been extensively investigated. As a hobby he kept tropical fish.
Six months previously the patient had been referred to secondary care for a painful ulcer resulting from an injury that he had sustained whilst cleaning his fish tank. The wound on his left index finger had failed to heal despite a three week antibiotic course. An ultrasound confirmed dactylitis and tenosynovitis. Two wound washouts were subsequently performed three weeks apart. At At the second procedure the wound was found to contain locules of pus and Mycobacterium marinum, an atypical mycobacterium that is the cause of fish tank granuloma, was isolated on culture.
An anti-tuberculous mycobacterial chemotherapy regime was commenced, consisting initially of rifampicin and ethambutol. On review in clinic five weeks prior to this admission, the patient had complained of nausea, sore eyes and a bitter taste in the mouth. His symptoms were attributed to rifampicin and this was therefore substituted with Clarithromycin; all other medications, including simvastatin 40mg daily, had remained unchanged.
On admission physical examination demonstrated a painful proximal myopathy predominantly affecting the lower limbs with no evidence of compartment syndrome. He had a healing wound over the ulnar aspect of the distal interphalageal joint on his left index finger. Cardiovascular, respiratory and abdominal examination was unremarkable however the patient was anuric.
INVESTIGATIONS If relevant
Biochemistry revealed sodium 137mmol/L, potassium 7.0mmol/L, urea 39.8mmol/L, creatinine 702μumol/L and creatine kinase 216440 U/L [range 0-40].
An abdominal ultrasound showed aa normal appearances of both kidneys with no evidence of hydronephrosis.
Chest radiograph demonstrated mild left basal atelectasis but the lung fields were otherwise clear, with no evidence of pulmonary oedema.
DIFFERENTIAL DIAGNOSIS If relevant /
TREATMENT If relevant
The patient was admitted to thethe intensive care unitunit and placed on continuous venovenous haemofiltration (CVVHDF). Twenty-four hours later he transferred to the renal ward for on-going management of his acute kidney injury secondary to rhabdomyolysis.
He remained an inpatient for 29 days, requiring ten further haemodialysis sessions whilst in hospital. Urine output increased gradually to 800mls per day, but then plateaued. Prior to discharge a tunnelled neck line was inserted for outpatient hospital haemodialysis.
Simvastatin treatment was stopped immediately upon admission. Anti-tuberculous mycobacterial medications were also withheld. On review the left index finger wound was found to have healed with some residual scar tissue and restriction of movement around the proximal interphalangeal joint. The respiratory team advised permanent discontinuation of the clarithromycin and ethambutol course.
OUTCOME AND FOLLOW-UP
Following discharge the patient required on-ggoing haemodialysis but there was evidence of improving renal function with increasing urine output. Tt.Three weeks following discharge his urine output had increased to 1600 mls/day, creatine kinase had fallen to 161 U/l and dialysis was discontinued. At 3 months from initial presentation the patient remains dialysisindependent. He remains under follow up due to persistent renal dysfunction (Cr>400µmol/l). He was not restarted on statins. Anti-tuberculous mycobacterial medications were also withheld. On review the left index finger wound was found to have healed with some residual scar tissue and restriction of movement around the proximal interphalangeal joint. No further anti-tuberculous chemotherapy was prescribed.
DISCUSSION Include a very brief review of similar published cases
Although the incidence of rhabdomyolysis in patients taking statins is reported to be low (estimated 1.6 cases per 100 000 person-years) 3 , a systematic review of statin safety noted the importance of preventable cases in those patients taking CYP3A4 inhibitors 4 . Law et al demonstrated in cases of rhabdomyolysis linked to simvastatin, lovastatin or atorvastatin approximately 60% of patients were also taking a CYP3A4 inhibitor, such as a macrolide antibiotic, as in this case 4 .
The risk of statin-induced myopathy is known to be dose-dependent 5 , and therefore drugs which inhibit the CYP34A pathway, through which simvastatin is metabolised, potentially increase exposure to the drug and its side-effects. The Medicines and Healthcare Products Regulatory Agency (MRHA) published updated guidance in 2012 highlighting that simvastatin is contra-indicated with macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to this risk profile 6 . Also contraindicated with simvastatin are: azole antifungals (e.g. itraconazole), HIV protease inhibitors (e.g. nelfinavir), nefazodone, ciclosporin, danazol andor gemfibrozil 6 . In addition, the dose of simvastatin must be restricted to 20mg maximum if the patient is taking either a calcium channel blocker (amlodipine, diltiazem, verapamil) or amiodarone 6 (table 1) .
Recent data supports the association between a variant (rs4149056) in SLCO1B1 gene and simvastatin-induced myopathy 7 . The gene encodes for OATP1B1, which is an organic anion transporter that facilitates hepatic uptake of statins. People who have this variant have reduced transporter function and experience higher blood plasma levels of simvastatin for the same administered dose compared with normal metabolisers.
The Clinical Pharmacogenetics Implementation Consortium have developed prescribing guidelines for Simvastatin in patients with the SLCO1B1 genotype advising lower doses and routine CK monitoring for patients known to be heterozygous or homozygous for the decreased-function allele 8 . Testing is not yet routinely available in the UK and the MRHA guidance is that if the genotype is known or can be tested this should be taken into account when prescribing high doses of simvastatin but suggest that alternative statins, that are not affected by the genotype, should be considered 9 .
Data from The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) collaborative group, which demonstrated the dose-dependent relationship between simvastatin and myopathy, has shown only a 6% reduction in major vascular events in patients taking 80mg of simvastatin compared to 20mg 810 . Therefore higher doses of simvastatin should be reserved for those with severe hypercholesterolaemia and high cardiovascular risk in whom the benefits outweigh the risks.
Patients with renal impairment are at higher risk of myopathy, and thus their statin dose should be reduced accordingly. The patient presented here, known to have chronic kidney disease stage 3a, should ideally have been on atorvastatin 20mg at presentation, rather than simvastatin 40mg, in accordance with NICE guidance 1 . The statin should then have been suspended when the patient was prescribed a course of clarithromycin.
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points -this is a required field
 Simvastatin is contra-indicated with macrolide antibiotics due to increased myopathy risk PATIENT'S PERSPECTIVE Optional but strongly encouraged -this has to be written by the patient or next of kin
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